News Briefing channel feed

Pro­teosta­sis shares whacked hard as CF drug falls short; Ad­vax­is ax­es tri­al plans in wake of a clin­i­cal hold

7 years ago

Swiss at­tor­ney gen­er­al is­n't pros­e­cut­ing No­var­tis for bribery; Madri­gal to raise $200M in stock sale

7 years ago

Roche gets pri­or­i­ty re­view for Hem­li­bra's sec­ond in­di­ca­tion; Ora­sis gets $13M B round for pres­by­opia eye drop

7 years ago

Ar­a­vive merges with strug­gling Ver­sar­tis, gain­ing ac­cess to Nas­daq; Si­lence Ther­a­peu­tics CEO Ali Mor­taza­vi leaves the RNAi biotech

7 years ago

Bio­gen snatch­es ex-Pfiz­er ex­ec as new EVP, cor­po­rate de­vel­op­ment; Io­n­is/Akcea get thumbs up from EMA com­mit­tee on in­ot­ersen

8 years ago

Astel­las, Fi­bro­Gen hit pri­ma­ry end­point in PhI­II; vTv inks PDE4 in­hibitor deal with New­soara

8 years ago

Zai Lab li­cens­es pso­ri­a­sis drug from Crescen­do; Hit­Gen, Li­on raise cash for dis­cov­ery and de­vel­op­ment work in Asia

8 years ago

Astel­las wins pri­or­i­ty re­view for AML drug; Take­da share­hold­ers re­volt against $62B Shire deal

8 years ago

Re­cro shares tank on FDA’s CRL; Prothena ax­es more than half of staff; No­vo inks $200M deal with Epi­gen

8 years ago

Ox­ford spin­out grabs $9M A round for pep­tide plat­form; blue­bird gets a 'break­through' at the FDA

8 years ago

Gates Foun­da­tion, UK gov­ern­ment back CARB-X, boost an­tibi­otics fund­ing past $500M

8 years ago

GSK gets Eu­ro­pean OK for HIV drug Ju­lu­ca; Akari dealt non-com­pli­ance no­tice from Nas­daq

8 years ago

As­traZeneca drops or di­vests a slate of drugs in lat­est quar­ter­ly up­date; Pierre Fab­re ex­tends a di­ag­nos­tic col­lab­o­ra­tion with Roche

8 years ago

Why would Co­hen reach out to No­var­tis, but not Roche?; WuXi Bi­o­log­ics blue­prints big R&D/man­u­fac­tur­ing com­plex

8 years ago

As­traZeneca steps up its use of Em­u­late's 'or­gan chip' tech; An­sun Bio­phar­ma's parain­fluen­za ther­a­py at­tracts $85M from Asian VCs

8 years ago

Dai­ichi Sankyo adds $484M pact to its on­go­ing Zymeworks col­lab­o­ra­tion; Sur­face spins out of Im­prim­is with $20M raise

8 years ago

Chi­na's CStone ramps up yet an­oth­er PD-1 clin­i­cal tri­al for sol­id tu­mors; Take­da faces prof­it de­cline on loss of Vel­cade ex­clu­siv­i­ty

8 years ago

Celldex ax­es two more pro­grams to cut costs fol­low­ing glem­bat­u­mum­ab fail­ure; Zio­pharm stock slides on halt­ed brain can­cer tri­al

8 years ago

Astel­las signs Asian li­cens­ing deal with Aquinox; Ar­a­vive touts ear­ly-stage PoC

8 years ago

Fin­land's Faron ham­mered by sur­pris­ing piv­otal tri­al flop; CFO Si­mon Dinge­mans ex­its GSK in lead­er­ship makeover

8 years ago

Atara en­lists Juno co-founder Michel Sade­lain in CAR-T ef­fort; Valeant no more, Bausch is the new mar­quee name

8 years ago

Al­ler­gan aes­thet­ics chief David Moataze­di be­comes CEO of Evo­lus; CARB-X in­vests $6.2M in­to Melin­ta's next-gen an­tibi­otics

8 years ago

Re­gen­eron ditch­es high­er dose of pain drug fas­inum­ab in PhI­II, trig­ger­ing safe­ty scare; In a small win for Al­ny­lam, FDA de­lays re­view for Ion­is' in­ot­ersen

8 years ago

Af­ter rais­ing VC mon­ey weeks ago, Uni­ty tacks on an $85M IPO; Abpro sets terms for $60M IPO

8 years ago
First page Previous page 59606162636465 Next page Last page
A service from the Financial Times